फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

tillomed pharma gmbh - levosimendan - infuusiokonsentraatti, liuosta varten - 2.5 mg/ml - levosimendaani

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamidi - epilepsia - epilepsialääkkeet, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.